Wall Street analysts have projected Covid-19 vaccine revenues for (PFE) (ticker: PFE) and Moderna (MRNA) to be a fraction in 2022 of what they have been in 2021, despite both companies planning to continue to increase their manufacturing capacity. Vaccines from competitors, meanwhile, have fallen out of favor amid repeated setbacks. Now, just in the past few days, Wall Street is catching up with the obvious: Sales of Moderna and Pfizer’s Covid-19 vaccines aren’t going away anytime soon.
